BioVoice News September 2017 Issue 4 Volume 2 | Page 17

MAJOR PLAYERS IN INDIA IN THE VACCINE MARKET 1. Serum Institute of India 2. Panacea Biotech 3. Venkateshwara Hatcheries Private 4. Indian Immunological 5. GlaxoSmithKline Pharmaceuticals 6. Aventis Pharma 7. Shantha Biotechnics 8. Eli Lilly India 9. Haffkine Bio Pharmaceutical Corporation Ltd (HBCL) 10. Intervet India 11. Lupin 12. Avesthagen 13. Wyeth 14. Sanofi 15. Merck world. Serum institute is currently one of the largest manufacturers of MMR group of vaccines and Pentavalent group of vaccines in the world, present in 147 countries. This is the second overseas acquisition for the company after it bought a plant during 2012 in Holland. The rapid growth of the global vaccine market would lead to increased competition and experts say that it would even resemble the pharmaceutical market. There would be a distinct first mover advanta ge for companies launching their vaccines early in the Indian market with funding from various government agencies. Competition in the market is set to increase with the entry of more traditional companies. India must develop its own national strategies to meet its vaccination needs within its budgetary constraints. However, the new initiatives and new strategic approach by the regulatory bodies can build the industry’s confidence. That in turn will be able to bring about positive changes to enable India as an emerging leader in global vaccine industry. For the Indian vaccine industry to continue on the current accelerated growth path for the next decade as well, it is critical that the current strength to proactively embrace innovation and build pipeline of complex products is channelized and intensified in an appropriately rewarding ecosystem. The current domination in the low and middle income vaccine supply has to to move on and make a competitive mark in the regulated markets. BIOVOICENEWS.COM 17